Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Aerobiology and pollution (40)
  • Allergen immunotherapy (81)
  • AllergoOncology (14)
  • Allergy asthma and a sport (4)
  • Allergy diagnosis (222)
  • Allied health and primary care (19)
  • Anaphylaxis (112)
  • Artificial Intelligence (12)
  • Asthma (138)
  • Basic immunology (57)
  • Biologicals (75)
  • Biomarkers (54)
  • Comparative veterinary allergology (1)
  • COVID19 (9)
  • Dermatology (123)
  • Drug allergy (158)
  • ENT (24)
  • Environmental allergy and climate change (30)
  • Eosinophilic esophagitis (21)
  • Epidemiology (64)
  • Epithelial cell biology (8)
  • Food allergy (193)
  • Genomics and proteomics (17)
  • Immune deficiencies and autoimmunity (77)
  • Immunomodulation and nutrition (13)
  • Infections (24)
  • Insect venom hypersensitivities (19)
  • Mastocytosis and mast cells (23)
  • Microbiome (8)
  • Occupational allergy (24)
  • Ocular allergy (5)
  • One Health (13)
  • Pediatrics (131)
  • Prevention (38)
  • Systems medicine (13)
Poster available until
  • Until platform closure (46)
Poster categories
  • x e-Thematic Poster Session (93)
  • x Thematic Poster Session (980)
keywords
Session Reference
  • L-TPS01 (11)
  • L-TPS02 (15)
  • L-TPS03 (14)
  • L-TPS04 (12)
  • L-TPS05 (13)
  • L-TPS06 (8)
  • L-TPS07 (11)
  • L-TPS08 (7)
  • L-TPS09 (13)
  • L-TPS10 (13)
  • L-TPS11 (12)
  • L-TPS12 (14)
  • L-TPS13 (13)
  • L-TPS14 (11)
  • L-TPS15 (7)
  • L-TPS16 (5)
  • L-TPS17 (13)
  • L-TPS18 (9)
  • L-TPS19 (10)
  • L-TPS20 (12)
  • L-TPS21 (12)
  • TPS01 (12)
  • TPS02 (8)
  • TPS03 (14)
  • TPS04 (9)
  • TPS05 (15)
  • TPS06 (11)
  • TPS07 (13)
  • TPS08 (9)
  • TPS09 (9)
  • TPS10 (16)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (15)
  • TPS16 (15)
  • TPS17 (12)
  • TPS18 (10)
  • TPS19 (7)
  • TPS20 (11)
  • TPS21 (5)
  • TPS22 (3)
  • TPS23 (4)
  • TPS25 (12)
  • TPS26 (14)
  • TPS27 (12)
  • TPS28 (16)
  • TPS29 (16)
  • TPS30 (14)
  • TPS31 (15)
  • TPS32 (16)
  • TPS33 (14)
  • TPS34 (17)
  • TPS35 (15)
  • TPS36 (12)
  • TPS37 (15)
  • TPS38 (13)
  • TPS39 (14)
  • TPS40 (13)
  • TPS41 (9)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (8)
  • TPS47 (7)
  • TPS48 (5)
  • TPS49 (5)
  • TPS51 (1)
  • TPS52 (12)
  • TPS53 (8)
  • TPS54 (15)
  • TPS55 (1)
  • TPS57 (11)
  • TPS58 (1)
  • TPS59 (12)
  • TPS60 (9)
  • TPS61 (1)
  • TPS62 (8)
  • TPS63 (10)
  • TPS64 (11)
  • TPS65 (7)
  • TPS66 (9)
  • TPS67 (9)
  • TPS68 (19)
  • TPS69 (8)
  • TPS70 (9)
  • TPS71 (11)
  • TPS72 (6)
  • TPS73 (5)
  • TPS75 (4)
1073 results
Thumbnail

D1.347 - Biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms

Thumbnail

D1.35 - Lipid transfer protein and Profilin-associated food-dependent exercise-induced anaphylaxis: A case series

Thumbnail

D1.350 - A patient-centric approach to chronic rhinosinusitis with nasal polyps (CRSwNP): developing tools to improve disease management and outcomes

Thumbnail

D1.351 - The impact of Lactobacillus on the expression of NLRP3, IL-1β and HMGB1 in women with endometriosis associated infertility

Thumbnail

D1.353 - When eosinophils surpass the limits without a known cause

Thumbnail

D1.355 - Impact of mesothelin in women with endometriosis

Thumbnail

D1.36 - Prevalence of thaumatin and Alternaria co-sensitization

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.388 - Frequency of Allergic Diseases in Various Age Groups

Thumbnail

D1.389 - How Youth Understand and Manage Risks Associated with Their Food Allergy in Everyday Life

Thumbnail

D1.390 - Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR

Thumbnail

D1.391 - Comparing Dietary Advancement Therapy for IgE-Mediated Egg Allergy in Primary and Tertiary Care: A Retrospective Review

Thumbnail

D1.392 - Allergic Rhinitis Patients Appear to be at Risk of Lower Quality of Life and Higher Probability of Moderate or Severe Anxiety: Results of an Online Survey in Lithuania

Thumbnail

D1.393 - Building Local Capacity and Improving Access to Specialist Allergist Care for Indigenous Patients in Northern Quebec, Canada

Thumbnail

D1.394 - Characteristics, healthcare provision and expectations of patients with atopic dermatitis as part of the ADCompanion study to evaluate a digital form of care

Thumbnail

D1.397 - Eosinophilic Pneumonia Triggered by Toxocara canis in a Patient with Kartagener Syndrome: A Case Report Highlighting Diagnostic Challenges and Interdisciplinary Management

Thumbnail

D1.398 - Retrospective study of the effect of bacterial immunotheraphy on patients with chronic respiratory diseases

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • Page 50
  • Page 51
  • Current page 52
  • Page 53
  • Page 54
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM